PRMT3 and breast adenocarcinoma: Studies have shown that the differentially expressed tumor suppressor DAL-1 (differentially expressed in adenocarcinoma of the lung)/4.1B interacts with PRMT3 and inhibits its ability to methylate substrates, affecting the development and progression of lung and breast adenocarcinomas, suggesting that PRMT3 may be an effective inhibitory target for the treatment of cancer [59,60].